22,954 Shares in Grail, Inc. (NASDAQ:GRAL) Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. acquired a new stake in shares of Grail, Inc. (NASDAQ:GRAL - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 22,954 shares of the company's stock, valued at approximately $410,000. Charles Schwab Investment Management Inc. owned approximately 0.07% of Grail as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. Douglas Lane & Associates LLC acquired a new position in shares of Grail during the 4th quarter valued at $3,034,000. A. D. Beadell Investment Counsel Inc. bought a new position in Grail during the fourth quarter valued at about $430,000. FNY Investment Advisers LLC acquired a new position in Grail during the fourth quarter worth about $26,000. 180 Wealth Advisors LLC bought a new stake in Grail in the fourth quarter worth about $1,681,000. Finally, B & T Capital Management DBA Alpha Capital Management acquired a new stake in Grail in the 4th quarter valued at about $387,000.

Insiders Place Their Bets

In other news, CFO Aaron Freidin sold 1,816 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $31.20, for a total value of $56,659.20. Following the completion of the sale, the chief financial officer now directly owns 335,170 shares of the company's stock, valued at $10,457,304. This represents a 0.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Robert P. Ragusa sold 7,625 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $31.21, for a total transaction of $237,976.25. Following the completion of the sale, the chief executive officer now owns 828,662 shares of the company's stock, valued at approximately $25,862,541.02. The trade was a 0.91 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,550 shares of company stock worth $360,436.

Remove Ads

Analyst Upgrades and Downgrades

Separately, Morgan Stanley lifted their price objective on shares of Grail from $16.00 to $20.00 and gave the stock an "equal weight" rating in a research note on Tuesday, March 18th.

Grail Stock Down 10.6 %

Shares of NASDAQ:GRAL traded down $2.63 during mid-day trading on Friday, hitting $22.25. The stock had a trading volume of 1,620,475 shares, compared to its average volume of 1,218,467. The company's 50 day moving average is $34.24 and its 200-day moving average is $22.80. Grail, Inc. has a 12-month low of $12.33 and a 12-month high of $63.99.

Grail (NASDAQ:GRAL - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.41) by $2.55. The business had revenue of $38.25 million during the quarter, compared to analysts' expectations of $35.33 million. As a group, research analysts expect that Grail, Inc. will post -15.15 earnings per share for the current year.

Grail Company Profile

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.